Lexeo Therapeutics (LXEO) Interest Coverage Ratio (2022 - 2026)
Lexeo Therapeutics (LXEO) reported Interest Coverage Ratio of 8.09 for Q1 2026, up 87.24% on a YoY basis from 4.32 in Q1 2025, and up 81.03% sequentially from 42.65 in Q4 2025.
Lexeo Therapeutics (LXEO) Interest Coverage Ratio (2022 - 2026) Analysis & Trends
Lexeo Therapeutics (LXEO) has 5 years of Interest Coverage Ratio data on file, last reported at 8.09 in Q1 2026.
- For the quarter ending Q1 2026, Interest Coverage Ratio rose 87.24% year-over-year to 8.09; the trailing twelve-month figure through Mar 2026 stood at 35.43 (up 50.58% YoY), and the FY2025 full-year result was 0.92, up 94.54% from the prior year.
- Interest Coverage Ratio rose to 8.09 in Q1 2026, from 42.65 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 1.28 in Q1 2024 to a low of 379.92 in Q4 2022.
- A 5-year average of 65.93 and a median of 27.56 in 2023 frame the typical range for Interest Coverage Ratio.
- Across the five-year window, Interest Coverage Ratio jumped 96.52% in 2023 and slumped 4867.23% in 2025, its largest moves.
- Tracing LXEO's Interest Coverage Ratio over 5 years: stood at 379.92 in 2022, then gained by 21.17% to 299.48 in 2023, then soared by 82.81% to 51.47 in 2024, then increased by 17.14% to 42.65 in 2025, then jumped by 81.03% to 8.09 in 2026.
- Business Quant data shows LXEO's Interest Coverage Ratio at 8.09 in Q1 2026, 42.65 in Q4 2025, and 2.49 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -157.58 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 7.60 |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -0.38 |
| 10 | Lexeo Therapeutics | 379.94 Mn | 379.94 Mn | - | -8.09 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.09 |
| Dec 31, 2025 | -42.65 |
| Sep 30, 2025 | -2.49 |
| Jun 30, 2025 | -3.32 |
| Mar 31, 2025 | -63.42 |
| Dec 31, 2024 | -51.47 |
| Sep 30, 2024 | -5.71 |
| Jun 30, 2024 | -1.34 |
| Mar 31, 2024 | -1.28 |
| Dec 31, 2023 | -299.48 |
| Sep 30, 2023 | -2.25 |
| Jun 30, 2023 | -27.56 |
| Mar 31, 2023 | -35.20 |
| Dec 31, 2022 | -379.93 |
| Sep 30, 2022 | -64.75 |